Skip to content

The efficacy of combined facial exercise with botulinum toxin treatment in clinical practice in Thai patients with hemifacial spasm: A randomized controlled pilot crossover study

The efficacy of combined facial exercise with botulinum toxin treatment in clinical practice in Thai patients with hemifacial spasm: A randomized controlled pilot crossover study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180403002
Enrollment
40
Registered
2018-04-03
Start date
2018-05-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemifacial spasm on botolinum toxin Hemifacial spasm Botolinum toxin Facial massage facail exercise

Interventions

Patients within intervention groups are introduced facial squeezing technique by video&#45
program before the injection of BTX&#45
A (The technique is shown in appendix 5 according to the protocol&#44
modified from the original one of O’Reilly et al.16) After BTX&#45
A injection the patients are then asked to squeeze his/her faces immediately after the injection for 5 minutes as assigned. ,While the patients who are allocated to no facial exercise group are asked
Experimental Procedure/Surgery,No Intervention No treatment
BTX&#45
A injection plus facial exercise using squeezing technique for 5 minutes ,No facial exercise (BTX&#45
A injection alone)

Sponsors

Faculty of Medicine, Siriraj Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - Patients with diagnosis of hemifacial spasm by authorized neurologist in Siriraj Hospital, Mahidol University, Bangkok, Thailand - Patients are currently treated with BTX-A in the clinic with any degree of response - Age 18-80 years

Exclusion criteria

Exclusion criteria: - Patients who have other neurological problems e.g. stroke, blepharospasm, dementia - Patients who are physically dependent - Patients who are illiterate - Patients who are blind - Patients who cannot squeeze his/her own face - Patients currently treated with oral anticoagulants (NOACs, Vitamin K antagonists)

Design outcomes

Primary

MeasureTime frame
The efficacy of treatment measured by QoL with HFS-30 severity score 3 months HFS 30 score,Time to onset of drug 3 months Days

Secondary

MeasureTime frame
SMC grading system, time to peak effect, duration of BTX-A effect 3 months days

Countries

Thailand

Contacts

Public ContactPrachaya Srivanitchapoom

SIriraj hospital

cloundbuffy@hotmail.com02-419-7101-2

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026